API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The proceeds will advance the development of PLX-8394 (plixorafenib), the company’s novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations in patients with BRAF-altered advanced solid and central nervous system tumors.
Lead Product(s): Plixorafenib
Therapeutic Area: Oncology Product Name: PLX-8394
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SR One
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing August 23, 2023
Details:
FORE8394 is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF, it is being investogated for the treatment of primary brain and central nervous system (CNS) malignancies.
Lead Product(s): Plixorafenib,Cobicistat
Therapeutic Area: Oncology Product Name: FORE8394
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
FORE8394 is a selective inhibitor of mutated BRAF. It was designed to target a wide range of BRAF mutations while sparing wild-type forms of RAF. It is being developed for BRAF-mutated solid and brain tumors.
Lead Product(s): Plixorafenib,Cobicistat
Therapeutic Area: Oncology Product Name: FORE8394
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
FORE8394 is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF. It was designed to target a wide range of BRAF mutations while sparing wild-type forms of RAF.
Lead Product(s): Plixorafenib
Therapeutic Area: Oncology Product Name: FORE8394
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
FORE8394 demonstrated confirmed single agent overall response rate of 43% and median duration of response of 17.8 months in MAPK-inhibitor naïve, V600+ population; 71% experienced clinical benefit of at least 24 weeks.
Lead Product(s): Plixorafenib
Therapeutic Area: Oncology Product Name: FORE8394
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
FORE8394 is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF. It was designed to target a wide range of BRAF mutations while sparing wild type forms of RAF.
Lead Product(s): Plixorafenib
Therapeutic Area: Oncology Product Name: FORE8394
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2022
Details:
Novellus’ BRAF program focuses on patient populations for which there are currently no FDA-approved BRAF inhibitors, including BRAF fusions and BRAF-mutated gliomas.
Lead Product(s): Plixorafenib
Therapeutic Area: Oncology Product Name: PLX-8394
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novellus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 23, 2020
Details:
Proceeds will fund the clinical development of PLX-8394 for patients with BRAF fusions and glioma patients with BRAF mutations.
Lead Product(s): Plixorafenib
Therapeutic Area: Oncology Product Name: PLX-8394
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pontifax
Deal Size: $57.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 21, 2020
Details:
Under the terms of the agreement, Plexxikon grants Novellus rights to research, develop, manufacture and exclusively commercialize PLX8394 worldwide.
Lead Product(s): Plixorafenib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novellus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 03, 2020